Literature DB >> 29253430

Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study.

Mirjam J Knol1, Susan J M Hahné2, Jay Lucidarme3, Helen Campbell4, Hester E de Melker2, Stephen J Gray3, Ray Borrow3, Shamez N Ladhani4, Mary E Ramsay4, Arie van der Ende5.   

Abstract

BACKGROUND: Since 2009, the incidence of meningococcal serogroup W disease has increased rapidly in the UK because of a single strain (the so-called original UK strain) belonging to the hypervirulent sequence type-11 clonal complex (cc11), with a variant outbreak strain (the so-called 2013 strain) emerging in 2013. Subsequently, the Netherlands has had an increase in the incidence of meningococcal serogroup W disease. We assessed the temporal and phylogenetic associations between the serogroup W outbreaks in the Netherlands and England, and the historical serogroup C outbreaks in both countries.
METHODS: For this observational cohort study, we used national surveillance data for meningococcal serogroup W and serogroup C disease in the Netherlands and England for the epidemiological years (July to June) 1992-93 to 2015-16. We also did whole genome sequencing and core genome multilocus sequence typing (1546 loci) on serogroup W disease isolates from both countries for surveillance years 2008-09 to 2015-16. We used Poisson regression to compare the annual relative increase in the incidence of serogroup W and serogroup C between both countries.
FINDINGS: In the Netherlands, the incidence of meningococcal serogroup W disease increased substantially in 2015-16 compared with 2014-15, with an incidence rate ratio of 5·2 (95% CI 2·0-13·5) and 11% case fatality. In England, the incidence increased substantially in 2012-13 compared with 2011-12, with an incidence rate ratio of 1·8 (1·2-2·8). The relative increase in the Netherlands from 2014-15 to 2015-16 was 418% (95% CI 99-1248), which was significantly higher than the annual relative increase of 79% (61-99) per year in England from 2011-12 to 2014-15 (p=0·03). Cases due to meningococcal serogroup W cc11 (MenW:cc11) emerged in 2012-13 in the Netherlands. Of 29 MenW:cc11 cases found up to 2015-16, 26 (90%) were caused by the 2013 strain. For both the current serogroup W outbreak and the historical serogroup C outbreak, the increase in incidence started several years later in the Netherlands than in England, the rate of increase was higher in the Netherlands, and age distributions were similar in both countries.
INTERPRETATION: Given the historical similarities of meningococcal serogroup W with meningococcal serogroup C emergence, the rapid expansion of the MenW:cc11 2013 strain in the Netherlands, its high case fatality, and the availability of a safe and effective vaccine, urgent consideration is needed for public health interventions in the Netherlands and other affected countries to prevent further serogroup W cases and deaths. FUNDING: National Institute for Public Health and the Environment (Netherlands), Academic Medical Center (Netherlands), and Public Health England.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29253430     DOI: 10.1016/S2468-2667(17)30157-3

Source DB:  PubMed          Journal:  Lancet Public Health


  28 in total

Review 1.  [What is verified for travel vaccinations?]

Authors:  Tomas Jelinek
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 2.  Epidemiology of invasive meningococcal disease in Greece, 2006-2016.

Authors:  Anastasia Flountzi; Theano Georgakopoulou; Sooria Balasegaram; Konstantinos Kesanopoulos; Athanasia Xirogianni; Anastasia Papandreou; Georgina Tzanakaki
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-15       Impact factor: 3.267

3.  Genomic surveillance of Neisseria meningitidis serogroup W in Portugal from 2003 to 2019.

Authors:  Célia Bettencourt; Alexandra Nunes; João Paulo Gomes; Maria João Simões
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-11-17       Impact factor: 5.103

4.  Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial.

Authors:  Markus Knuf; Mika Rämet; Nina Breinholt Stærke; Isabelle Bertrand-Gerentes; Yaël Thollot; Siham B'Chir; Habiba Arroum; Philipp Oster
Journal:  Hum Vaccin Immunother       Date:  2022-04-21       Impact factor: 4.526

5.  The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015-2018.

Authors:  Anna D Loenenbach; Arie van der Ende; Hester E de Melker; Elisabeth A M Sanders; Mirjam J Knol
Journal:  Clin Infect Dis       Date:  2020-05-06       Impact factor: 9.079

6.  Whole genome sequencing of Neisseria meningitidis W isolates from the Czech Republic recovered in 1984-2017.

Authors:  Michal Honskus; Zuzana Okonji; Martin Musilek; Jana Kozakova; Pavla Krizova
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

7.  Phase Variation of NadA in Invasive Neisseria meningitidis Isolates Impacts on Coverage Estimates for 4C-MenB, a MenB Vaccine.

Authors:  Luke R Green; Jay Lucidarme; Neelam Dave; Hannah Chan; Stephen Clark; Ray Borrow; Christopher D Bayliss
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

8.  Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018.

Authors:  Mirjam J Knol; Wilhelmina Lm Ruijs; Laura Antonise-Kamp; Hester E de Melker; Arie van der Ende
Journal:  Euro Surveill       Date:  2018-04

9.  Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized study.

Authors:  Germán Áñez; James Hedrick; Michael W Simon; Shane Christensen; Robert Jeanfreau; Eddy Yau; Judy Pan; Emilia Jordanov; Mandeep S Dhingra
Journal:  Hum Vaccin Immunother       Date:  2020-03-25       Impact factor: 3.452

10.  Impact of COVID-19 pandemic and the lockdown on invasive meningococcal disease.

Authors:  Muhamed-Kheir Taha; Ala-Eddine Deghmane
Journal:  BMC Res Notes       Date:  2020-08-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.